In several different assays, TAK-441 was shown to have equal affinity for wild-type and mutated SMO, while Vismodegib and cyclopamine showed reduced affinity for the D473H mutant suggesting that TAK-441 may be clinically relevant to treating Vismodegib-resistant, Shh pathway-driven cancers [107]. The gene discussed is SMO; the disease is cancer.